Program:
Start Year:
2022
Why did you choose Duke for your residency training?
I chose Duke because I knew I would receive excellent clinical training in a supportive environment and ample opportunity to pursue fellowship training after residency. All the departmental and program leadership made me feel welcomed and appreciated. I grew up in Idaho and moved to Durham after college in 2012. I feel so fortunate to stay in this incredible city while benefiting from the endless opportunities at Duke.
What excites you about the residency program at Duke Ob/Gyn?
I am most excited about my co-residents -- they are an inspiring and accomplished group of doctors who care for their patients and each other.
What are your career goals?
I plan to pursue additional training in Maternal-Fetal Medicine and hope to stay in academic medicine focused on improving pregnancy outcomes through research.
Describe your research interests/goals:
I am a data-scientist and most-interested in prenatal genetic testing.
What are your hobbies?
Like most people, my wife and I love all things food and beverage. Durham has amazing food options and a farmer’s market that runs all year long. When I have time on Saturday mornings, I work with a local farm selling produce at the market, have apprenticed at local restaurants, and run a bourbon club. I also love catching some live jazz at Sharp Nine Gallery.
Education & Training
Undergraduate school & graduation year:
The College of Idaho, 2012
Medical school & graduation year:
University of North Carolina School of Medicine, 2022
Publications
Filer DL, Hoffman K, Sargis RM, Trasande L, Kassotis CD. On the Utility of ToxCast-Based Predictive Models to Evaluate Potential Metabolic Disruption by Environmental Chemicals. Environ Health Perspect. 2022 May;130(5):57005. doi: 10.1289/EHP6779. Epub 2022 May 9. PMID: 35533074; PMCID: PMC9084331.
Filer DL, Kuo F, Brandt AT, Tilley CR, Mieczkowski PA, Berg JS, Robasky K, Li Y, Bizon C, Tilson JL, Powell BC, Bost DM, Jeffries CD, Wilhelmsen KC. Pre-capture multiplexing provides additional power to detect copy number variation in exome sequencing. BMC Bioinformatics. 2021 Jul 20;22(1):374. doi: 10.1186/s12859-021-04246-w. PMID: 34284719; PMCID: PMC8293537.
Filer DL, Mieczkowski PA, Brandt A, Gilmore KL, Powell BC, Berg JS, Wilhelmsen KC, Vora NL. Noninvasive prenatal exome sequencing diagnostic utility limited by sequencing depth and fetal fraction. Prenat Diagn. 2022 May;42(5):567-573. doi: 10.1002/pd.6009. Epub 2021 Jul 21. PMID: 34265090; PMCID: PMC8760355.
DL Filer, K Hoffman, RM Sargis, L Trasande, and CD Kassotis (May 2022). On the Utility of ToxCast-Based Predictive Models to Evaluate Potential Metabolic Disruption by Environmental Chemicals. Environ Health Perspect 130(5): 57005. PMID: 35533074.
DL Filer, PA Mieczkowski, A Brandt, KL Gilmore, BC Powell, JS Berg, KC Wilhelmsen, and NL Vora (May 2022). Noninvasive prenatal exome sequencing diagnostic utility limited by sequencing depth and fetal fraction. Prenat Diagn 42(5): 567–573. PMID: 34265090.
DL Filer, F Kuo, AT Brandt, CR Tilley, PA Mieczkowski, JS Berg, K Robasky, Y Li, C Bizon, JL Tilson, BC Powell, DM Bost, CD Jeffries, and KC Wilhelmsen (July 2021). Pre-capture multiplexing provides additional power to detect copy number variation in exome sequencing. BMC Bioinformatics 22(1): 374. PMID: 34284719.
DL Filer, P Kothiya, RW Setzer, RS Judson, and MT Martin (Feb. 2017). tcpl: the ToxCast pipeline forhigh-throughput screening data. Bioinformatics 33(4): 618–620. PMID: 27797781. DL Filer, HB Patisaul, T Schug, DM Reif, and KA Thayer (Dec. 2014). Test driving ToxCast: endocrine profiling for 1858 chemicals included in phase II. Current Opinion in Pharmacology 19: 145–152. PMID: 25460227.
Complete works: https://scholar.google.com/citations?user=ekNCMNcAAAAJ&hl=en
Curriculum vitae: https://daynefiler.com/cv/filer_cv.pdf